ArticleBMJ case reports2016
Relapsing CD8+ encephalitis-looking for a solution.
Article in BMJ case reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- HIV-associated CD8+ encephalitis confirmed by cerebrospinal fluid flow cytometry: first case in Colombia.Frontiers in medicine · 2025Article
- Learning from cerebrospinal fluid drug-resistant HIV escape-associated encephalitis: a case report.Virology journal · 2023Article
- CD8 Encephalitis in HIV: A Review of This Emerging Entity.Journal of clinical medicine · 2023Review
- CD8 Encephalitis: A Diagnostic Dilemma.Diagnostics (Basel, Switzerland) · 2022Article
- Reversible Small Vessel Vasculitis and Encephalitis in HIV Antiretroviral Resistance.Journal of neuropathology and experimental neurology · 2021Article
- CD8 encephalitis with CSF EBV viraemia and HIV drug resistance, a case series.Brain, behavior, & immunity - health · 2020Article
- Relapse of Symptomatic Cerebrospinal Fluid HIV Escape.Current HIV/AIDS reports · 2020Review
- Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.Clinical drug investigation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD8+ encephalitis (CD8+E) is an emerging and incompletely understood HIV-associated neurological syndrome, typically presenting as a steroid-responsive subacute encephalopathy with prominent white matter changes in patients with apparently well-controlled HIV infection. Some cases can be associated with the phenomenon of 'viral escape' (disproportionate replication within the cerebrospinal fluid), but the most important pathophysiology of CD8+E is thought to involve an attack on HIV-infected CD4+ lymphocytes by autoreactive CD8+ cells. We report a case of CD8+E where the initial positive response to steroid treatment was followed by several relapses on withdrawal. This led to the use of mycophenolate mofetil (MMF) as a long-term steroid-sparing agent, which is the first time this approach has been reported in the literature. The patient has now been on treatment with MMF for 10 months and it has been possible to taper the steroids down to a minimal maintenance dose without further relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.